Is PolyPid Ltd. (PYPD) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 3.5% / 30% | 16.2% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 3.5% / 33% | 16.2% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 12.5% / 33% | 58.0% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 3.5% / 33% | 16.2% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 12.5% / 33% | 58.0% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -366.3% | |
| Return on Assets (ROA) | -86.7% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$28M |
| Free Cash Flow | -$28M |
| Total Debt | $3M |
| Debt-to-Equity | 25.5 |
| Current Ratio | 2.0 |
| Total Assets | $22M |
Price & Trading
| Last Close | $4.32 |
| 50-Day MA | $4.41 |
| 200-Day MA | $3.83 |
| Avg Volume | 64K |
| Beta | 1.5 |
|
52-Week Range
$2.30
| |
About PolyPid Ltd. (PYPD)
PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is PolyPid Ltd. (PYPD) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), PolyPid Ltd. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is PolyPid Ltd.'s debt ratio?
PolyPid Ltd.'s debt ratio is 3.5% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 12.5%.
What are PolyPid Ltd.'s key financial metrics?
PolyPid Ltd. has a market capitalization of $82M. Return on equity stands at -366.3%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.